 Home > Biochemistry News > Biotechnology News > Reduce the risk of patient death by 49%, TCR therapy receives FDA priority review qualification

Reduce the risk of patient death by 49%, TCR therapy receives FDA priority review qualification

 Last Update: 2021-09-03
 Source: Internet
 Author: User

Tags

specialized products company

malassezia furfur treatment

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

Today, Immunocore announced that regulatory agencies in the United States and the European Union have accepted the company’s regulatory application for the treatment of tebentafusp (IMCgp100) under investigation for the treatment of adult patients with metastatic uveal melanoma (mUM), these patients are HLA-A *02:01 positive

Tebentafusp is a bispecific molecule

It is worth noting that the company’s corresponding technology allows TCR to recognize cancer antigens in cells with high affinity, which is expected to break through the limitations of existing antibody drugs and increase the number of recognizable targets from 10% to 90%

▲The design of this type of TCR therapy mimics the natural TCR mechanism of action (picture source: reference [2])

This application is based on the positive results of the randomized phase 3 clinical trial IMCgp100-202

(The original text has been deleted)

Reference materials:

[1] Immunocore Announces that US Food and Drug Administration and European Medicines Agency accept Biologics License Application and Marketing Authorization Application for Tebentafusp in Metastatic Uveal Melanoma.

[2] Bertil E.

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

Related Products

L-Ascorbate-2-Monophosphate Feed Grade

CAS No.: 109620-90-8

Feed Grade

Potassium Sorbate from reliable manufacturer

CAS No.: 590-00-1

Food Grade

Doxycycline Hydrochloride

CAS No.: 10592-13-9

Pharmaceutical Grade

Hot Tags

united states jobs(223)

jobs united states(236)

1 year treasury(277)

1 year subscription(296)

single use technology(195)

announcements today(81)

ups united states(221)

united states logo(227)

80 20 company(94)

healthy food name(42)

Hot Articles

The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.